The Dr Is In | World Medical Innovation Forum - Gene and Cell Therapy

The Dr. Is In

The Dr. Is In

The Future of GCT: Identifying Market Opportunities

Understanding long-term Gene and Cell Therapy investment complexities requires a keen awareness of where the science and the
markets are headed. That’s why “The Doctor is In” in these updates on the latest GCT technologies. Presented by Mass General Brigham clinicians and innovators from the front lines of care, the sessions are co-hosted by expert analysts from Bank of America and include interactive discussion and Q&A. Join in these concurrent lunch-time programs on Monday and Tuesday. Check the app and hallway signage for room locations.

2022 Panels

Leveraging Novel Mechanisms for Vaccine and Immunotherapy Development

In this session, Dr. Poznansky will share how research and development of vaccines and immunotherapy are safely accelerated from research lab to the patient leveraging novel mechanisms.

Alexandria Hammond, PhD, Associate, Global Research, BofA Securities 
Mark Poznansky, MD, PhD, Director, Vaccine and Immunotherapy Center, MGH; Professor of Medicine, HMS

Gene and Epigenetic Editing in the Development of Treatments for Deafness

In this session, Dr. Edge will discuss how deafness is treated by drugs and gene editing approaches using targets discovered in cochlear organoids.

Geoff Meacham, PhD, Managing Director, Global Research, BofA Securities 
Albert Edge, PhD, Eaton Peabody Professor of Otolaryngology, HMS, Mass Eye and Ear

Newborn Sequencing and Prevention of Rare Diseases: A New Challenge

In this session, Drs. Robert Green and Adam Shaywitz will discuss how the early detection and prevention of rare diseases is imminent and represents an enormous public health opportunity. 

Jason Gerberry, Managing Director, Global Research, BofA Securities
Robert Green, MD, Director, Genomes2People Research Program, BWH; Professor of Medicine, HMS
Adam Shaywitz, MD, PhD, CMO, BridgeBio Gene Therapy

Repair, Replace, Regrow: The Advancement of Regenerative Medicine

In this session, hear from experts in their field as they discuss the need and importance of regenerative medicine for the advancement in the treatment of diseases such as diabetes, kidney disease and blood disorders. 

Jason Zemansky, PhD, Vice President, Global Research, BofA Securities
Joseph Bonventre, MD, PhD, Chief, Division of Renal Medicine, BWH; Samuel A. Levine Distinguished Professor of Medicine and Constantine L. Hampers Distinguished Chair, HMS
David Scadden, MD, Director, Center for Regenerative Medicine, MGH; Gerald and Darlene Jordan Professor of Medicine, HMS

Single Gene Correction in the Brain: Delivering Where it Matters Most

In this session, Dr. Eichler will discuss the impact of gene defects across the lifespan and how timing and delivery of new genetic therapies is transforming the field of neurogenetics. 

Tazeen Ahmad, Managing Director, Global Research, BofA Securities
Florian Eichler, MD, Director, Center for Rare Neurological Diseases, MGH; Associate Professor of Neurology, HMS

Smart Materials: Non-viral Vectors for Gene Therapy

In this session, Dr. Artzi will share how an integrative approach of combining materials science, chemistry, imaging, and biology enables targeted delivery of gene therapy. 

Alec Stranahan, PhD, Vice President, Equity Research, BofA Securities
Natalie Artzi, PhD, Assistant Professor of Medicine, HMS

Personalizing Cancer Care through RNA Therapies

In this session, Dr. Peruzzi will discuss how RNA for cancer therapy is a versatile of a tool for a protean problem.

Jason Gerberry, Managing Director, Global Research, BofA Securities
Pierpaolo Peruzzi, MD, PhD, Neurosurgeon and Principal Investigator, BWH; Assistant Professor of Neurosurgery, HMS

Designing for Success: Clinical Trial Approaches for Rare and Ultra-Rare Diseases

In this session, Dr. Vavvas will discuss examples of clinical trials in rare diseases and share insights into how clinical trials should be approached for rare and ultra-rare diseases and how study design is not a one-size fits all. 

Tazeen Ahmad, Managing Director, Global Research, BofA Securities
Demetrios Vavvas, MD, PhD, Associate Director of the Retina Service, Mass Eye and Ear; Solman and Libe Friedman Professor of Ophthalmology, Co-Director Ocular Regenerative Medical Institute, HMS

A New Hope: Cell Therapy and Transplantation for Parkinson’s Disease

In this session, hear experts weigh in on the possibilities of cell therapy development and transplantation for the treatment of Parkinson’s Disease. What does the futures hold and how do we get there? 

Greg Harrison, Vice President, Global Research, BofA Securities
Bob Carter, MD, PhD, Chairman, Department of Neurosurgery, MGH; William and Elizabeth Sweet Professor of Neurosurgery, HMS
Todd Herrington, MD, PhD, Director, Deep Brain Stimulation Program, MGH; Assistant Professor of Neurology, HMS
Kwang-Soo Kim, PhD, Director, Molecular Neurobiology Laboratory, McLean; Professor of Neuroscience and Psychiatry, HMS
Jeffrey Schweitzer, MD, PhD, Neurosurgeon, MGH; Assistant Professor of Neurosurgery, HMS

The Inner Workings of Gene Therapy Manufacturing

In this session, Dr. Nikiforow will provide insights into the world of gene therapy manufacturing and the complexities of scaling, costs and insurance reimbursement. 

Michael Ryskin, Director, Global Research, BofA Securities
Sarah Nikiforow, MD, PhD, Medical Director, Cell Manipulation Core Facility, Technical Director, Immune Effector Cell Therapy Program, DFCI; Assistant Professor, HMS

The Road Ahead: Regulatory Challenges for Gene and Cell Therapy

In this session, Dr. Marks will discuss the ins and outs of regulatory challenges for biological products and therapies in gene and cell therapy and the responsibility to assure safety and effectiveness. 

Geoff Meacham, PhD, Managing Director, Global Research, BofA Securities
Peter Marks, MD, PhD, Director, Center for Biologics Evaluation and Research, FDA

The Mysterious Dark Genome

Dark genome, accounting for ~98.5% of the human genome and containing the non-coding part, offers unprecedented opportunity to look for novel elements that could play a role in human health. This non-coding region consists of repeat elements, enhancers, regulatory sequences and non-coding RNAs. This session will explore this exciting new frontier in biology and how to translate this so called “junk” and previously ignored genome into potential novel therapeutics. 

Angela Shen, MD, Vice President, Strategic Innovation Leaders, Mass General Brigham Innovation
Richard Young, PhD, Professor, Whitehead Institute, MIT
Rosana Kapeller, MD, PhD, Co-Founder, President & CEO, ROME Therapeutics
Josh Mandel-Brehm, President & CEO, CAMP4 Therapeutics
Amir Nashat, PhD, Managing Partner, Polaris Ventures
Issi Rozen, Venture Partner, GV